In March, two biotechnology companies were given the greenlight by the Food and Drug Administration, or FDA, to conduct trials transplanting genetically-modifie ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

March 27, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics ... first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for ...

Net Loss: BioXcel Therapeutics had a net loss of $10.9 million for the fourth quarter of 2024, compared to a net loss of $22.3 million for the same period in 2023. For the full year of 2024 ...

United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The business’s fifty day moving average is $342.26 and its 200-day moving average is $356.31.

WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced the successful closing of the ...

PLANO, Texas & BALTIMORE, March 25, 2025--(BUSINESS WIRE)--Secretome Therapeutics ... of the first patient in its Phase 1 clinical trial evaluating STM-01 as a treatment for heart failure with ...

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference Oncotelic Therapeutics, Inc. Tue, Mar 25, 2025, 9:00 AM 7 ...

Secretome Therapeutics ... (nCPC), today announced dosing of the first patient in its Phase 1 clinical trial evaluating STM-01 as a treatment for heart failure with preserved ejection fraction ...

MANILA, Philippines – First Gen Corp. said its net income fell by 12 percent in 2024 as it suffered lower revenues and incurred higher expenses to sustain operations. In a disclosure on Friday ...